Biolegend, 628202, Purified anti-p53 Antibody, 100μg

p53 is a 53 kD protein that forms tetramers and functions as a tumor suppressor and transcriptional activator of genes that inhibit growth and/or invasion, cell cycle checkpoint after irradiation, DNA repair, apoptotic induction, signal transduction, and cell adhesion. This protein is localized to the nucleus when activated and can be upregulated by genotoxic or other cellular stresses. p53 is modified by phosphorylation, acetylation, ribosylation, ubiquitination, and sumoylation; ubiquination targets p53 for degradation via mdm2. This protein interacts with a variety of proteins including mdm2, mdmx, topoisomerase I, PML3, Bcl-X L , Bcl-2, Chk1, JNK, p38, HIPK2, CK2, DNA-PK, p300/CBP, PCAF, PARP1, and HDAC1-3. Mutant p53 associates with p63 and p73.
100μg
Verified Reactivity: Human
Reported Reactivity: Non-Human Primate
Antibody Type: Monoclonal
Host Species: Mouse
Immunogen: Amino acid: 20-25 of human p53
Formulation: This antibody is provided in Tris-buffered solution, pH 8.0, containing 0.09% sodium azide at 0.5 mg/ml.
Preparation: This antibody was purified by affinity chromatography.
Concentration: 0.5 mg/ml
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C.
Application: WB - Quality tested ChIP - Verified IHC-P - Reported in the literature, not verified in house
Recommended Usage: Each lot of this antibody is quality control tested by Western blotting. Western blotting, suggested working dilution(s): Use 5 µg per 5 ml antibody dilution buffer for each mini-gel. The recommended starting antibody to chromatin ratio is 1 µg of antibody and 5 µg of chromatin per IP. Optimal antibody to chromatin ratio should be determined by the end user. It is recommended that the reagent be titrated for optimal performance for each application.
Application References(PubMed link indicates BioLegend citation): Terada T, et al. 1994. Mod. Pathol. 7:249. (IHC) Lanoix D, et al. 2013. Mol Cell Endocrinol. 381:35. PubMed
Product Citations: Zhao Y, et al. 2018. Int J Oncol. 52:1959. PubMed Katkoori VR, et al. 2017. Oncotarget. 8:76574. PubMed Mandriota S, et al. 2010. J Biol Chem. 285:13092. PubMed Lanoix D, et al. 2013. Mol Cell Endocrinol. 381:35. PubMed Wang WW, et al. 2021. J Am Chem Soc. 143:16700. PubMed Amrenova A, et al. 2021. PLoS One. 16:e0249059. PubMed
RRID: AB_439766 (BioLegend Cat. No. 628201) AB_439767 (BioLegend Cat. No. 628202)
Structure: Tetramer; 53 kD
Distribution: Nuclear when activated
Function: Tumor suppressor, transcriptional activator of genes that inhibit growth and/or invasion, cell cycle checkpoint after irradiation, DNA repair, apoptotic induction, signal transduction, cell adhesion
Interaction: mdm2, mdmx, TopoI, PML3, Bcl-XL, Bcl-2, Chk1, JNK, p38, HIPK2, CK2, DNA-PK, p300/CBP, PCAF, PARP1, HDAC1-3; mutant p53 associates with p63, p73
Modification: Phosphorylation, Acetylation, Ribosylation, Ubiquitination, Sumoylation
Cell Type: Mesenchymal Stem Cells
Biology Area: Apoptosis/Tumor Suppressors/Cell Death, Cell Biology, Cell Cycle/DNA Replication, DNA Repair/Replication, Stem Cells, Transcription Factors
Molecular Family: Phospho-Proteins
Antigen References: 1. Vogelstein B, et al. 1992. Cell. 70:523. 2. Shieh S, et al. 1997. Cell. 91:325. 3. Mihara M, et al. 2003. Mol. Cell 11:577. 4. Saito S, et al. 2003. J. Biol. Chem. 278:37536.
Regulation: Ubiquinated for degradation via mdm2. Upregulated by genotoxic or other cellular stresses
Gene ID: 7157
UniProt: View information about p53 on UniProt.org
Clone: BP53-12
Regulatory Status: RUO
Other Names: Tumor protein p53 (TP53)
Isotype: Mouse IgG2a, κ